查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1679375

肺腺癌治療市場規模、佔有率、趨勢分析報告：按療法、最終用途、地區和細分市場預測，2025-2030 年

Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), By End-use (Hospitals, Specialty Clinics), By Region (North America, Europe), And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

肺腺癌治療市場的成長和趨勢

根據Grand View Research, Inc.的最新報告，全球肺腺癌治療市場預計到2030年將達到111.8億美元，2025年至2030年期間的複合年成長率為10.7%。

該市場提供廣泛的治療方案、技術和服務，旨在管理和治療肺腺癌（非小細胞肺癌（NSCLC）的一種亞型）。

某些地區吸菸率的上升、空氣污染和職業危害等環境因素是市場成長的主要驅動力。隨著越來越多的人被診斷出患有肺腺癌，對有效治療方案的需求也在增加。

人們對肺癌症狀和風險因素的認知不斷提高，對市場產生了重大影響。旨在提高戒菸和早期發現意識的公共衛生宣傳活動導致越來越多的人在出現症狀後儘快尋求醫療幫助。

2023年10月，百時美施貴寶以每股58美元收購了Mirati，股權總價值為48億美元，潛在價值為58億美元，包括或有價值權，其中包括用於治療晚期非小細胞肺癌的KRASG12C抑制劑KRAZATI（adagrasib）。

肺腺癌治療市場報告重點

  • 化療部分在 2024 年佔據了最大的收入佔有率，為 36%。這主要歸功於其在肺癌治療中的既定作用和治療方法的持續進步。
  • 預計免疫療法領域將成長最快，預測期內複合年成長率為 13.5%。肺腺癌盛行率的不斷上升推動了對先進治療方案的需求，這些方案與化療和放射線治療等傳統治療方法相比，具有更好的療效和安全性。
  • 醫院憑藉其完善的基礎設施和提供多種先進癌症治療的能力，在 2024 年佔據了最大的收益佔有率，達到 63.9%。
  • 預計專科診所部門在預測期內將以最快的複合年成長率成長。這一成長是由個人化和標靶治療治療的需求不斷成長，以及患者對肺癌治療方案的認知不斷提高所推動的。
  • 由於肺腺癌發病率上升以及對創新治療方法的高度重視，北美肺腺癌治療市場在 2024 年將佔據最大的收入佔有率，為 39.5%。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章肺腺癌治療市場變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 分析——波特五力分析
    • PESTLE分析
    • 管道分析

第4章肺腺癌治療市場：治療業務分析

  • 2024年和2030年的治療市場佔有率
  • 治療細分儀表板
  • 2018 年至 2030 年按療法分類的市場規模、預測與趨勢分析
  • 化療
  • 標靶治療
  • 免疫療法
  • 放射線治療
  • 其他

5. 肺腺癌治療市場-最終用途業務分析

  • 2024 年及 2030 年終端用途市場佔有率
  • 最終用途細分儀表板
  • 2018 年至 2030 年按最終用途分類的市場規模、預測和趨勢分析
  • 醫院
  • 專科門診
  • 其他

第6章肺腺癌治療市場：按地區估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030年各國情況
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 按國家/地區，2018 年至 2030 年
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 2018-2030年各國情況
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 2018-2030年各國情況
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 參與者概述
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Pfizer Inc.
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Merck KGaA（EMD Serono）
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • F. Hoffmann-La Roche Ltd
Product Code: GVR-4-68040-428-6

Lung Adenocarcinoma Treatment Market Growth & Trends:

The global lung adenocarcinoma treatment market size is expected to reach USD 11.18 billion by 2030, registering a CAGR of 10.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. This market offers a range of therapeutic options, technologies, and services aimed at managing and treating lung adenocarcinoma, which is a subtype of non-small cell lung cancer (NSCLC).

The rise in smoking rates in certain regions and environmental factors such as air pollution and occupational hazards are key growth drivers for market growth. As more individuals are diagnosed with lung adenocarcinoma, there is a corresponding demand for effective treatment options.

Increased awareness about lung cancer symptoms and risk factors has significantly influenced the market. Public health campaigns aimed at educating populations about smoking cessation and early detection led to more individuals seeking medical attention sooner after experiencing symptoms.

In October 2023, Bristol Myers Squibb acquired Mirati for USD 58.00 per share, totaling USD 4.8 billion in equity value, potentially rising to USD 5.8 billion with contingent value rights, including KRAZATI (adagrasib), a KRASG12C inhibitor for advanced non-small cell lung cancer.

Lung Adenocarcinoma Treatment Market Report Highlights:

  • The chemotherapy segment accounted for the largest revenue share of 36% in 2024. This is primarily due to its established role in lung cancer management and ongoing advancements in treatment regimens.
  • The immunotherapy segment is expected to witness the fastest growth, with a projected CAGR of 13.5% over the forecast period. The rising prevalence of lung adenocarcinoma has increased the demand for advanced treatment options that offer better efficacy and safety compared to traditional therapies such as chemotherapy and radiation.
  • Hospitals accounted for the largest revenue share of 63.9% in 2024, driven by their comprehensive infrastructure and ability to provide a wide range of advanced cancer treatments.
  • The specialty clinics segment is expected to grow at the fastest CAGR over the forecast period. This growth is driven by the rising demand for personalized and targeted therapies, along with increasing patient awareness of lung cancer treatment options.
  • North America lung adenocarcinoma treatment market held the largest revenue share of 39.5% in 2024, driven by the rising incidence of lung adenocarcinoma and a strong focus on innovation in treatment approaches.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Lung Adenocarcinoma Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Lung adenocarcinoma treatment market: Type Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2030
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy Market, 2018 - 2030 (USD Million)
  • 4.5. Targeted therapy
    • 4.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
  • 4.7. Radiation therapy
    • 4.7.1. Radiation Therapy Market, 2018 - 2030 (USD Million)
  • 4.8. Other
    • 4.8.1. Other Market, 2018 - 2030 (USD Million)

Chapter 5. Lung adenocarcinoma treatment market: End use Business Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 5.5. Specialty Clinics
    • 5.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Other Market, 2018 - 2030 (USD Million)

Chapter 6. Lung adenocarcinoma treatment market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 6.4. North America
    • 6.4.1. North America Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Norway
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Norway Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Denmark Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Pfizer Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. AstraZeneca
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Bristol-Myers Squibb Company
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Eli Lilly and Company
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Boehringer Ingelheim International GmbH
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Novartis AG
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Merck KGaA (EMD Serono)
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. AbbVie Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Astellas Pharma Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. F. Hoffmann-La Roche Ltd
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global lung adenocarcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 5 Global lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 8 North America lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 9 U.S. lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 U.S. lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 12 Canada lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 13 Mexico lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 14 Mexico lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Europe lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 Europe lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 18 UK lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 19 UK lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Germany lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 21 Germany lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 France lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Italy lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 25 Italy lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Spain lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 27 Spain lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Norway lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Norway lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Denmark lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 31 Denmark lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Sweden lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 33 Sweden lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Japan lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 Japan lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 39 China lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 40 China lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 41 India lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 India lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Australia lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 44 Australia lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 45 South Korea lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 46 South Korea lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Thailand lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 48 Thailand lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 49 Latin America lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 Latin America lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Brazil lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 53 Brazil lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Argentina lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 55 Argentina lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 59 South Africa lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 South Africa lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 63 UAE lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 64 UAE lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Kuwait lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 66 Kuwait lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Lung Adenocarcinoma Treatment Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment and end use outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Lung adenocarcinoma treatment market dynamics
  • Fig. 12 Lung adenocarcinoma treatment market: Porter's five forces analysis
  • Fig. 13 Lung adenocarcinoma treatment market: PESTLE analysis
  • Fig. 14 Lung adenocarcinoma treatment market: Treatment segment dashboard
  • Fig. 15 Lung adenocarcinoma treatment market: Treatment market share analysis, 2024 & 2030
  • Fig. 16 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 17 Targeted therapy market, 2018 - 2030 (USD Million)
  • Fig. 18 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 19 Radiation therapy market, 2018 - 2030 (USD Million)
  • Fig. 20 Other market, 2018 - 2030 (USD Million)
  • Fig. 21 Lung adenocarcinoma treatment market: End use segment dashboard
  • Fig. 22 Lung adenocarcinoma treatment market: End use market share analysis, 2024 & 2030
  • Fig. 23 Hospitals market, 2018 - 2030 (USD Million)
  • Fig. 24 Specialty clinics market, 2018 - 2030 (USD Million)
  • Fig. 25 Other market, 2018 - 2030 (USD Million)
  • Fig. 26 Lung Adenocarcinoma Treatment Market revenue, by region
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 North America lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. country dynamics
  • Fig. 30 U.S. lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada country dynamics
  • Fig. 32 Canada lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 33 Mexico country dynamics
  • Fig. 34 Mexico lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 36 UK country dynamics
  • Fig. 37 UK lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany country dynamics
  • Fig. 39 Germany lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 France country dynamics
  • Fig. 41 France lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy country dynamics
  • Fig. 43 Italy lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 Spain country dynamics
  • Fig. 45 Spain lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway country dynamics
  • Fig. 47 Norway lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden country dynamics
  • Fig. 49 Sweden lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Denmark country dynamics
  • Fig. 51 Denmark lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Japan country dynamics
  • Fig. 54 Japan lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 China country dynamics
  • Fig. 56 China lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 India country dynamics
  • Fig. 58 India lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 Australia country dynamics
  • Fig. 60 Australia lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea country dynamics
  • Fig. 62 South Korea lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 63 Thailand country dynamics
  • Fig. 64 Thailand lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Latin America lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 66 Brazil country dynamics
  • Fig. 67 Brazil lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 68 Argentina country dynamics
  • Fig. 69 Argentina lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 MEA lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 77 Kuwait country dynamics
  • Fig. 78 Kuwait lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 79 Company categorization
  • Fig. 80 Company market position analysis
  • Fig. 81 Strategic framework